Schering IL-10 has "very good" efficacy, toxicity data in early clinicals, exec tells Alex. Brown.
Executive Summary
SCHERING-PLOUGH IL-10 EFFICACY, TOXICITY DATA appear to bode well for the biosynthetic interleukin-10 product, Senior VP-Investor Relations and Corporate Communications Geraldine Foster suggested May 14 at the Alex. Brown health care seminar in Baltimore. IL-10 has had "some very good early stage trials in terms of efficacy and lack of toxicity," she said. The product is in clinicals for Crohn's disease and ulcerative colitis. IL-10 also is in early clinicals for rheumatoid arthritis.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth